← Back to patent-cliff list
CAS 165674-31-7
4-ethyl-7,8-dihydro-1H,10H-spiro[pyrano[3,4-f]indolizine-6,2'-[1,3]dioxolan]-10-one
Codes: BELOH-009
Application context (from source-drug indications)
Non-small cell lung cancerBelotecan HydrochlorideOvarian cancerBelotecan HydrochlorideSolid tumourBelotecan Hydrochloride
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Belotecan Hydrochloride | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(S)-4-ethyl-4-hydroxy-7,8-dihydro-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione→4-ethyl-1,4,7,8-tetrahydro-3H,10H-spiro[pyrano[3,4-f]indolizine-6,2'-[1,3]dioxolane]-3,10-dione→4-ethyl-3-hydroxy-3,4,7,8-tetrahydro-1H,10H-spiro[pyrano[3,4-f]indolizine-6,2'-[1,3]dioxolan]-10-one→4-ethyl-7,8-dihydro-1H,10H-spiro[pyrano[3,4-f]indolizine-6,2'-[1,3]dioxolan]-10-one→(4S)-4-ethyl-3,4-dihydroxy-3,4,7,8-tetrahydro-1H,10H-spiro[pyrano[3,4-f]indolizine-6,2'-[1,3]dioxolan]-10-one→(4S)-4-ethyl-4-hydroxy-10-oxo-4,7,8,10-tetrahydro-1H,3H-spiro[pyrano[3,4-f]indolizine-6,2'-[1,3]dioxolan]-3-yl acetate→(4S)-4-ethyl-4-(methoxymethoxy)-10-oxo-4,7,8,10-tetrahydro-1H,3H-spiro[pyrano[3,4-f]indolizine-6,2'-[1,3]dioxolan]-3-yl acetate→(4S)-4-ethyl-3-hydroxy-4-(methoxymethoxy)-3,4,7,8-tetrahydro-1H,10H-spiro[pyrano[3,4-f]indolizine-6,2'-[1,3]dioxolan]-10-one→(S)-4-ethyl-4-(methoxymethoxy)-1,4,7,8-tetrahydro-3H,10H-spiro[pyrano[3,4-f]indolizine-6,2'-[1,3]dioxolane]-3,10-dione→(S)-4-ethyl-4-hydroxy-1,4,7,8-tetrahydro-3H,10H-spiro[pyrano[3,4-f]indolizine-6,2'-[1,3]dioxolane]-3,10-dione→2-(1,3-dioxolan-2-yl)aniline→(S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.